Hypertension & heart
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Hypertension & heart

on

  • 1,153 views

 

Statistics

Views

Total Views
1,153
Views on SlideShare
1,077
Embed Views
76

Actions

Likes
0
Downloads
51
Comments
1

2 Embeds 76

http://www.cardiositeindia.com 63
http://cardiositeindia.com 13

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • YES
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Echocardiographic studies have demonstrated that hypertensive patients can have any of these patterns of LV geometry. 26 , 28 Classification of LV geometry based on LV mass and relative wall thickness (the ratio of LV wall thickness to diastolic dimension).28 Depicted schematically are cross sections of the left ventricle. The striped area represents LV wall thickness, and the area of the inner circle represents LV volume. Adapted from Sehgal and Drazner26 (copyright © 2007, Elsevier) and Khouri et al27 (copyright © 2010, the American Heart Assocaition).

Hypertension & heart Presentation Transcript

  • 1. Hypertension & Heart Dr Akshay Mehta Dr B Nanavati Hospital Asian Heart Institute
  • 2. Hypertensive Heart DiseaseTrue or False ?ALL the following are examples of hypertensive heart disease : CHD LVH LVF Arrhythmias Conduction system abnormality Aortic Regurgitation
  • 3. Definition : Hypertensive heart disease is a constellation of abnormalities including coronary artery disease, left ventricular hypertrophy (LVH), systolic and diastolic dysfunction, and their clinical manifestations including arrhythmias, conduction abnormalities and symptomatic heart failure, that are caused by the direct or indirect effects of elevated BP
  • 4. Hypertensive Heart Disease• Left ventricular hypertrophy• LV dysfunction: Diastolic Systolic• Heart Failure Diastolic Systolic• Arrhythmia, conduction abnormalities• CHD• AR
  • 5. Hypertensive CARDIO VASCULAR DISEASE includes:  Aortic aneurysm  Aortic dissection  PAD
  • 6. Left Ventricular Hypertrophy- LVH Increase in mass of LV
  • 7. LVH15-20% of hypertension pts develop LVHThe risk of LVH is increased 2-fold by associated obesity
  • 8. Classification of LV geometry based on LV mass andrelative wall thickness (the ratio of LV wall thickness to diastolic dimension) Drazner M H Circulation 2011;123:327-334 Copyright © American Heart Association
  • 9. LVH – concentric v/s eccentric responseGenetic factors may influence the response to pressure overload and, specifically, whether concentric or eccentric hypertrophy develops
  • 10. Is regression of LVH possible ? Yes No
  • 11. Hypertension and LV Dysfunction Diastolic dysfunction : Normal EF• Usually, but not invariably, accompanied by LVH• However, may be as common as 33% in hypertensive without LVH Systolic d dysfunction• Reduced EF with or without IHD
  • 12. Hypertension and HFo Hypertension accounts for 25% cases of HFo In elderly it accounts for 68% cases of HFo In patients with hypertension, the risk of heart failure is increased by 2-fold in men and by 3- fold in women
  • 13. The 7 pathways in the progression from hypertension to heart failure. Drazner M H Circulation 2011;123:327-334 Copyright © American Heart Association
  • 14. • The 7 pathways in the progression from hypertension to heart failure.• Hypertension progresses to concentric (thick-walled) LVH (cLVH; pathway 1).• The direct pathway from hypertension to dilated cardiac failure (increased LV volume with reduced LVEF) can occur without (pathway 2) or with (pathway 3) an interval myocardial infarction (MI). Concentric hypertrophy progresses to dilated cardiac failure (transition to failure) most commonly via an interval myocardial infarction (pathway 4).• Recent data suggest that it is not common for concentric hypertrophy to progress to dilated cardiac failure without interval myocardial infarction (pathway 5).• Patients with concentric LVH can develop symptomatic heart failure with a preserved LVEF (pathway 6), and patients with dilated cardiac failure can develop symptomatic heart failure with reduced LVEF (pathway 7).• The influences of other important modulators of the progression of hypertensive heart disease, including obesity, diabetes mellitus, age, environmental exposures, and genetic factors, are not shown to simplify the diagram.• A thicker arrow depicts a more common pathway compared with a thinner arrow.• Adapted from Drazner.2 Copyright 2005 ©, the American Heart Association.
  • 15. Other sequelae of LVH• LA enlargement• Hypertension most common cause of atrial fibrillation in the Western hemisphere• In one study, nearly 50% of patients with atrial fibrillation had hypertension• Dangers of AF : Stroke LV decompensation-HF
  • 16. Diagnosis of LVH Which is more sensitive: ECG or Echo ?• ECG LVH in 5-10% of hypertensives• Echo LVH in 30 % of hypertensivesEcho sensitivity - 57% for mild and 98% for severe LVHECG sensitivity – 30% to 57 % for severe LVH
  • 17. Cut-off limits for left ventricular hypertrophy on Echo• The ASE/EAE guidelines :LV septal wall thickness >0.9 cm for women and >1.0 cm for men,LV mass/BSA >95 g/m2 for women and LV mass/BSA >115 g/m2 for men.
  • 18. ECG abnormalitiesLA enlargementLVHLV strain patternLAHB (50% had hypertn in one series)LBBB (70-80% had hypertension)
  • 19. LA enlargement, LVH with strain
  • 20. LVH criteria by ECG The Cornell criteria (most sensitive) are R wave in aVL plus an S wave in V3 of greater than 2.8 mV in men and greater than 2mV in women The Sokolow-Lyon criteria are an S wave in V1 plus an R wave in V5 or V6 of greater than 3.5mV or an R wave in V5 or V6 of greater than 2.6mV (most specific) The Gubner-Ungerleider criteria are an R wave in I plus an S wave in III of greater than 2.5mV Romhilt-Estes Criteria (A Point Score System)
  • 21. Romhilt-Estes Criteria (A Point Score System) Voltage Criteria Points • R wave or S wave in any limb lead >0.2mV or 3 S wave in lead V1 or V2 or R wave in V5 or V6 >0.3mV • LV strain (ST and T waves in direction 3 opposite to QRS direction) without digitalis • LV strain (ST and T waves in direction 1 opposite to QRS direction) with digitalis • LA enlargement (terminal negativity of 3 P waves in V1 >0.1mV deep and 0.04 seconds wide) Left-axis deviation greater than -30° 2 QRS duration greater than 0.09 seconds 1 Intrinsicoid deflection in V5 or V6 >0.05 seconds 1 Probable LVH is 4 points; definite LVH is 5 points. The sensitivity of these criteria is 50%, with a specificity of close to 95%.
  • 22. Risks of LVH Are due to Pressure overload & Neurohormonal activation• Myocyte hypertrophy• Collagen deposition & fibrosis• Medial hypertrophy of intramyocardial coronary arteries• Impaired cor reserve + Fibrosis :• Diastoic Dysfn and Diastolic HF• Also V arrhthymia, AF, stroke
  • 23. Hypertension and IHD• At least one RF for IHD present in almost all pts with hypertn• Abn LDLC in more than 75%• Diabetes in about 25%• Obesity in 60-70% of patients with hypertension----------------------------------------------------------Out of all Diabetics – 75% have hypertensionOut of all pts with CRF – 90% have hypertensionOut of all obese patients- 50% have some degree of hypertension
  • 24. Continuous gradient of risk with rise in BP
  • 25. IHD mortality rate in each decade of age versus usual BP at the start of that decade
  • 26. Absolute risk of CV disease over 5 years inpatients by systolic BP at specified levels ofother risk factors Source: The Lancet 2005; 365:434-441 (DOI:10.1016/S0140-6736(05)17833-7 )
  • 27. Symptoms & Signs of Hypertensive Heart Disease• LVH – No Symptoms, Loud S2, heaving apex, paradoxic split S2• Diastolic HF, Systolic HF – Dyspnea, S4, S3, JVP, Lung rales• CAD- Angina, MI• AF –syncope, palpitations -Precipitation of angina -Precipitation of heart failure
  • 28. Prognosis of LVH Increase in the cardiovascular mortality rate esp an increase in the risk of sudden cardiac death Concentric LVH poses the greatest risk of such events, as much as a 30% risk over a 10-year period 15% risk with asymmetric LVH and a 9% risk without any LVH. The degree of LVH, as assessed by LV mass index (LVMI), is also related to the cardiovascular mortality rate, a relative risk of 1.73 for men and 2.12 for women for each 50g/m2 increase in the LVMI over a 4-year period.
  • 29. Prognosis of Left ventricular diastolic dysfunction• Poor and affected by the presence of underlying coronary artery disease.• In one study, survival rates at 3 months, 1 year, and 5 years in patients with heart failure due to diastolic dysfunction were 86%, 76%, and 46%, respectively.• Even in patients with asymptomatic diastolic dysfunction due to hypertension, the risk of all-cause mortality and cardiovascular events is significantly increased, particularly with an increase in the pulmonary artery wedge pressure (PAWP).
  • 30. Prognosis of Left ventricular systolic dysfunction High mortality rate and depends on the symptoms and NYHA heart failure classification. The 5-year mortality rate for patients with heart failure due to systolic dysfunction approaches 20% 2-year mortality rate in patients with NYHA class IV classification is as high as 50%. Mortality rates have decreased with the use of ACE inhibitors and beta blockers, which improve LV function.
  • 31. Drugs for LVH regression• Least effective- direct vasodilators• Mildly effective – Diu, BB• Most effective- ACEI/ARB, CCB Data indicate that regression of lectrocardiographic LVH is associated with less hospitalization for heart failure in hypertensive patients
  • 32. Drugs for diastolic dysfn. and diastolic HFACE inhibitors, beta blockers, and non dihydropyridine calcium channel blockersCandesartan (“CHARM added” trial)Careful addition of Diuretics, NitratesAvoid Hydrallazine
  • 33. Treatment of left ventricular systolic dysfunctionBeta blockers (cardioselective or mixed alpha and beta), such as carvedilol, metoprolol XL, and bisoprololACEI/ARBDiureticsNO CCB
  • 34. Drugs for Systolic HFo Diuretics (predominantly loop diuretics)o Low-dose spironolactoneo ACEI/ARBo BBo Avoid CCB
  • 35. Drugs for Hypertension with high CHD risk• ACEI/ARBs• CCB• BB ??, Diu ??
  • 36. Drugs for Hypertension with stable anginaBBCCB (Diltiazem, Verapamil)CCB (Amlodepin with BB)NitratesACEI/ARBDiu
  • 37. Drugs for Hypertension with ACSBBACEI/ARBNitratesCCB –amlo with BB
  • 38. Drugs for Hypertension post MIBB- Carvedilol, Metoprolol, BisoprololACEI/ARBAldo Antagonists (recommended for use in post-MI patients with diabetes mellitus or who have an LV ejection fraction of less than 40%.)
  • 39. Goal BP in cardiac patients ?< 140/90< 130/80< 120/80< 110/60
  • 40. What proportion of hypertensives should take statins ?1. All2. Almost all3. Only the few with significant dyslipidemia
  • 41. Why almost all ? Hypertension significant RF for CHD Dyslipidemia v common in hypertensives Antihypertensives often inadequate to reduce risk Residual risk even when BP is normalized Good evidence from RCT’s Follow the Chinese - they ALL take lovastatin in form of red rice and other preparations
  • 42. Will you recommend aspirin for primary prevention in…• All hypertensives ?• Those at high risk only ?• Almost all hypertensives ?
  • 43. Conclusions:• Hypertension a significant risk factor for CHD and HF• These risks are preventable with early diagnosis and treatment• Not only is it important to bring BP to targets, but also how it is brought down- match the drug with the associated cardiac condition
  • 44. THANK YOU!!